Studying the therapeutic effect of umbilical cord stem cell in pneumonia caused by covid-19

Salama m. El- shennawy, Microbiology Unit, Shebin El-Kom Teaching Hospital, Egypt,M.D microbiology
Abdalla Abo Hassen, Chest consultantant, head of Tanta cardiothorathic center, Tanta, Elgharbia
Talal Ibrahim Hagag, ICU,Shebin El-Kom Teaching Hospital, Egypt.M.D critical care MedicineFollow
Asherf I Zahra, Head of cardiothorathic surgery ,MD Shebin El-Kom Teaching Hospital
Reham Salama, Clinical pathology,.Msc. clinical pathology
Mariam A. Fouad, Clinical pathology, Shebin El-Kom Teaching Hospital, Egypt.M.D clinical pathology

Article Type

Original Study

Subject Area

Internal Medicine

Abstract

Context: Coronavirus disease (COVID-19) with severe respiratory morbidity and mortality , rapidly spread all over the world, caused by an sever acute respiratory syndrome coronavirus 2 (SARS-CoV-2) varying from mild symptoms to pulmonary fibrosis( Li Z et al.,2020). Mesenchymal stem cells (MSCs) can have a critical role, by promoting the pulmonary parenchyma regeneration and subsequently decreasing the symptoms of COVID-19 and help immune system to act against the virus (WHO, 2020).Aim: to evaluate the efficacy and safety of using stem cell in the treatment of COVID-19patients.Setting and design: We performed this case control study during the period from November 2020 to April 2021.Methods and material: The study was conducted on patients with COVID 19 induced pneumonia at emergency room divided into two groups: group 1: included 10 patients as a control group and group 2 (n=5) with severe disease who received two cycles of UC-MSCs treatment one by inhalation and the other IV. Baseline characteristics of all patients and medical treatment were recorded. There were no serious adverse events associated with UC-MSCs infusion. Statistical analysis of the data: Data were fed to the computer and analyzed using IBM SPSS software package version 20.0. Result: After using stem cell there was no statistically significant decrease in Pao2/FIO2ratio more in cases after receives management. There was no difference in use of MSCs in survival of patient with sever late acute respiratory distress syndrome (ARDS) patients and control. Conclusion: UCMSCs treatment for patients with COVID-19 may be safe but not effective

IRB Number

HSH00031

Keywords

Coronavirus disease (COVID-19), (SARS-CoV-2), pulmonary fibrosis, Mesenchymal stem cells (MSCs) and acute respiratory distress syndrome (ARDS).

Recommended Citation

El- shennawy, Salama m.; Hassen, Abdalla Abo; Hagag, Talal Ibrahim; Zahra, Asherf I; Salama, Reham; and Fouad, Mariam A. (2023) "Studying the therapeutic effect of umbilical cord stem cell in pneumonia caused by covid-19," Journal of Medicine in Scientific Research: Vol. 6: Iss. 4, Article 9.
DOI: https://doi.org/10.59299/2537-0928.1028